Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

6 articles from the last 90 days matching "france"

ResearchPUBMED3 days ago

Characteristics of Patients with Myasthenia Gravis in the French Rare Disease Registry.

Researchers in France studied a group of patients with myasthenia gravis (a rare disease where muscles become weak and tired easily) who were treated at special centers between 2007 and 2021. They collected information about these patients' backgrounds, how their disease developed, and how long they lived. This study helps doctors understand more about this disease and how to care for patients better.

WHY IT MATTERSThis registry data provides real-world evidence about myasthenia gravis outcomes and patient characteristics in France, which can help identify gaps in care and inform treatment guidelines for MG patients across Europe.
Good to knowMyasthenia GravisRead →
Clinical trialCLINICALTRIALSApr 2

New Clinical Trial: Assessment of Femoral Failure Load and Fracture Risk in Rare Bone Disorders Using MEKANOS Tool. Case Study of Fibrous Dysplasia of Bone/McCune Albright Syndrome (NCT07507942)

Researchers in France are studying a new tool called MEKANOS that measures how strong bones are and predicts fracture risk in people with fibrous dysplasia, a rare bone disease. This clinical trial involves 20 patients and aims to solve a major problem doctors face: they currently have no good way to know which patients are at highest risk of bone breaks. The study could help doctors make better treatment decisions for this condition.

WHY IT MATTERSThis trial addresses a critical gap in fibrous dysplasia care—doctors currently lack reliable tools to predict which patients will experience fractures, making this the first systematic assessment of fracture risk in this population.
💬 Ask your doctorFibrous Dysplasia of BoneMcCune-Albright SyndromeRead →
Clinical trialCLINICALTRIALSMar 27

Trial Now Recruiting: A Pilot Study to Assess the Feasibility and Acceptability of Newborn Screening Using in Silico Panel-based Solo Genome Sequencing in France (NCT06875089)

Researchers in France are recruiting 5,000 newborns to test a new way of screening for rare diseases using genome sequencing—a complete reading of a baby's DNA. Instead of the current blood spot tests that check for only a few dozen conditions, this study will see if reading a baby's entire genome can safely and effectively find many more rare genetic diseases at birth. This is one of the first major studies in Europe to test this approach.

WHY IT MATTERSThis trial could expand newborn screening in France to detect dozens of additional rare genetic diseases at birth, potentially allowing earlier treatment and better health outcomes for babies with conditions that currently go undiagnosed until symptoms appear.
You can act on thisRare genetic diseases detectable at birthConditions currently missed by standard newborn screeningRead →
PolicyPUBMEDMar 26

Genomic pathway managers: a novel role in the genomic medicine care pathway in France-overview and perspectives.

France is creating a new type of healthcare worker called a Genomic Pathway Manager to help doctors order genetic tests for patients with rare diseases and cancer. These managers will make it easier for patients to get genetic testing by organizing the process and helping doctors understand when and how to use these tests. The goal is to make genetic testing available to more people across France starting in 2025.

WHY IT MATTERSIf you have a rare disease in France, this new system could help your doctor identify your condition faster through genetic testing, potentially leading to earlier diagnosis and treatment options.
Good to knowrare diseases (general)cancer genetic predispositionRead →
ResearchCLINICALTRIALSMar 26

Trial Now Recruiting: Collection of Biological Samples From Patients With Rare Neurological Diseases (NCT04698421)

Researchers at a hospital in France are collecting biological samples (like blood) from 1,000 patients with rare nervous system diseases that may be caused by the immune system attacking the body. These samples will help scientists find new ways to diagnose and treat these diseases by identifying special markers in the blood that show disease activity.

WHY IT MATTERSIf you have a rare autoimmune neurological disease, participating in this sample collection could help researchers discover new biomarkers and treatments specifically for conditions like yours.
You can act on thisAutoimmune neurological diseasesRare nervous system diseasesRead →
Clinical trialCLINICALTRIALSMar 26

Trial Now Recruiting: Genetic of Intellectual Deficiency and Autism Spectrum Disorders (RaDiCo-GenIDA) (NCT06871696)

Researchers in France are looking for 1,000 families with children who have intellectual disabilities or autism caused by genetic changes. Families will answer questions online about their child's health and development to help doctors better understand these conditions and create personalized treatment plans in the future.

WHY IT MATTERSThis study directly recruits families affected by genetic intellectual disability and autism spectrum disorder to build a database that could lead to personalized medicine approaches for these conditions.
You can act on thisGenetic Intellectual DisabilityAutism Spectrum DisorderRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases